@article{APS10960,
author = {Wen-xiang Ren and Hao Guo and Sheng-yan Lin and Si-yi Chen and Yao-ying Long and Liu-yue Xu and Di Wu and Yu-lin Cao and Jiao Qu and Bian-lei Yang and Hong-pei Xu and He Li and Ya-li Yu and An-yuan Zhang and Shan Wang and Yi-cheng Zhang and Ke-shu Zhou and Zhi-chao Chen and Qiu-bai Li},
title = {Targeting cytohesin-1 suppresses acute myeloid leukemia progression and overcomes resistance to ABT-199},
journal = {Acta Pharmacologica Sinica},
volume = {45},
number = {1},
year = {2023},
keywords = {},
abstract = {Adhesion molecules play essential roles in the homeostatic regulation and malignant transformation of hematopoietic cells. The dysregulated expression of adhesion molecules in leukemic cells accelerates disease progression and the development of drug resistance. Thus, targeting adhesion molecules represents an attractive anti-leukemic therapeutic strategy. In this study, we investigated the prognostic role and functional significance of cytohesin-1 (CYTH1) in acute myeloid leukemia (AML). Analysis of AML patient data from the GEPIA and BloodSpot databases revealed that CYTH1 was significantly overexpressed in AML and independently correlated with prognosis. Functional assays using AML cell lines and an AML xenograft mouse model confirmed that CYTH1 depletion significantly inhibited the adhesion, migration, homing, and engraftment of leukemic cells, delaying disease progression and prolonging animal survival. The CYTH1 inhibitor SecinH3 exerted in vitro and in vivo anti-leukemic effects by disrupting leukemic adhesion and survival programs. In line with the CYTH1 knockdown results, targeting CYTH1 by SecinH3 suppressed integrin-associated adhesion signaling by reducing ITGB2 expression. SecinH3 treatment efficiently induced the apoptosis and inhibited the growth of a panel of AML cell lines (MOLM-13, MV4-11 and THP-1) with mixed-lineage leukemia gene rearrangement, partly by reducing the expression of the anti-apoptotic protein MCL1. Moreover, we showed that SecinH3 synergized with the BCL2-selective inhibitor ABT-199 (venetoclax) to inhibit the proliferation and promote the apoptosis of ABT-199-resistant leukemic cells. Taken together, our results not only shed light on the role of CYTH1 in cell-adhesion-mediated leukemogenesis but also propose a novel combination treatment strategy for AML.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/10960}
}